Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 175

3 338 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 338
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 338 trials in Corbeil Essonnes

Open in trial search

Chronic myeloid leukaemia

Not recruiting

Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Anthos Therapeutics Inc.

Cerebral palsy

Not recruiting

Study on Botulinum Toxin A and Hyoscine for Treating Drooling in Children Over 4 with Cerebral Palsy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Hyoscine
  • Sponsor:Hospices Civils De Lyon

Ischaemic stroke

Not recruiting

Study on the Effectiveness of Dornase Alfa for Improving Blood Flow in Patients with Ischemic Stroke Eligible for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Anthos Therapeutics Inc.

Hyperoxaluria

Not recruiting

Long-Term Safety and Efficacy Study of Nedosiran Injection for Patients with Primary Hyperoxaluria

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nedosiran
  • Sponsor:Dicerna Pharmaceuticals Inc.

Acute lymphocytic leukaemia+6

Not recruiting

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Neuroendocrine carcinoma of the skin+9

Not recruiting

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Haemophagocytic lymphohistiocytosis

Not recruiting

Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Thalassaemia

Not recruiting

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.